IONS

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2001, for ISIS Pharmaceuticals, Inc. (Note: The input text refers to the registrant as ISIS Pharmaceuticals, Inc., though the request metadata mentions Ionis Pharmaceuticals, which is the company's later name). The company is a biopharmaceutical firm focused on the discovery and development of antisense drugs. As of June 30, 2001, the company had 42,247,956 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased to $7.6 million for the quarter (from $7.0 million in 2000) and $12.2 million for the six months (from $11.0 million in 2000). This was driven by a $2.5 million milestone payment from Pfizer and a licensing agreement with Merck.
• Expense Increases: Research and development expenses rose significantly to $19.9 million for the quarter (from $12.7 million in 2000) due to the advancement of 11 products in development, including Phase 3 trials. General and administrative expenses also increased slightly.
• Stock Option Compensation: The company recorded $1.4 million in stock option compensation for the quarter, compared to zero in the prior year, due to the accounting treatment of variable stock options.
• Interest Expense: Interest expense increased to $3.5 million for the quarter (from $3.1 million in 2000) due to increased debt balances on convertible facilities with Elan and accrued interest on long-term notes.
• Liquidity: Cash and cash equivalents decreased from $39.6 million at year-end 2000 to $12.7 million at June 30, 2001. Total liquid assets (cash + short-term investments) decreased from $127.3 million to $106.3 million, primarily due to operational funding and a $15.0 million cash payment for a license from Hybridon, Inc.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue operating losses for the next several years as development costs for preclinical and clinical trials increase. The company believes its current cash, investments, and contract revenue are sufficient to fund operations for the next 30 to 36 months.
• Recent Agreements:
  • Merck: Licensed preclinical Type 2 diabetes candidate ISIS 113715; received upfront payment and will receive milestone and royalty payments.
  • Hybridon: Acquired exclusive license to antisense chemistry patents for $15.0 million cash and $19.5 million in stock.
  • Celera: Entered a collaboration in July 2001 to identify biological roles of over 200 genes.
• Risk Factors:
  • Regulatory Approval: Failure to obtain FDA approval for drug candidates could materially harm the business.
  • Commercialization: No guarantee that approved products will be accepted by physicians or payors.
  • Partnership Dependence: Reliance on collaborative partners (e.g., Pfizer, Merck, Elan) for funding and development; failure of partners to continue funding could delay programs.
  • Intellectual Property: Risks regarding patent protection and potential litigation (e.g., suit filed against Sequitur, Inc. in July 2001).
  • Manufacturing: Challenges in scaling up manufacturing for oligonucleotide drugs at competitive costs.

Investor Verification Checklist

• Verify the status and timeline of the Phase 3 clinical trials for ISIS 3521 (non-small cell lung cancer) and ISIS 2302 (Crohn's disease).
• Confirm the terms and future milestone payment triggers in the Merck licensing agreement for ISIS 113715.
• Assess the impact of the Hybridon acquisition on the company's patent portfolio and future royalty obligations.
• Monitor the company's cash burn rate against the stated 30-36 month runway to determine the timing of potential future capital raises.
• Review the progress of the litigation against Sequitur, Inc. regarding the RNase H patent.
• Check for any updates on the Elan joint ventures (Orasense and HepaSense) and their contribution to revenue or losses.